COMMENCEMENT OF STUDY TO IMPROVE OSTEOPORE'S CRANIAL IMPLANTS THOUGH AI-POWERED DESIGN

Highlights :

- *A comparative study between Osteopore's existing cranial implant design process, and Singular Health Group Ltd's (ASX: SHG) ("Singular Health") new artificial intelligence design engine, has successfully commenced.*

- *The study commences after Singular concluded their Data61 project in partnership with CSIRO, with results showing a 91% accuracy in cranial implant generation in less than 4mins[1].*

- *The study seeks to collate empirical data to develop a pathway to full FDA approval for AI model and deployment in Osteopore cranial applications.*

- *The significance of this study lies in the design and process improvements for Osteopore's cranial products afforded by Singular Health's AI Technology, and could reduce product-to-customer timeframes and improve implant quality.*

- *The study is part of Osteopore's strategy to collaborate with a range of technologies to improve the efficacy of its regenerative implants and improve patient outcomes.*

14 March 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale empowering natural tissue regeneration, is pleased to announce it has commenced a study with Singular Health Group Ltd (ASX: SHG) ("Singular Health"), to improve the accuracy and workflow efficiency of Osteopore's customised cranial implants.

Osteopore's customised implants are developed through CT scans of patients which are provided by surgeons. The scans are processed by a software that converts them into 3D models, which can then be used to 3D print customised implants. The objective of Singular Health's AI design engine is to reduce modelling time, while maintaining or improving design accuracy.

---

[1] Refer to Singular Health Group Limited ASX announcement titled 'SHG & CSIRO AI Tool to Optimise Cranial Implant Procedures' dated 14 March 2022.

Since signing a binding memorandum of understanding (MOU) with Osteopore in October 2021, Singular Health has proceeded to evolve its design engine through a joint project with CSIRO Data61. Results from this joint project have enabled a cranial implant to be designed in less than 4 minutes with 91% accuracy.

Building on these results, Osteopore and Singular Health will commence a comparative study to collate empirical data to develop a pathway to full FDA approval for AI model and deployment in Osteopore cranial applications. The study will validate the accuracy and efficiency of the AI-model and the Company's 3Dicom Surgical software (whereby manual edits may be conducted to increase the implant accuracy to 100%) against Osteopore's existing workflow.

Some expected outcomes from this study will include a reduction in product-to-customer timeframes and improved implant quality. The commencement of this study is part of Osteopore's sustainable growth plan, which involves workflow improvements to deliver better service and products to customers.

Goh Khoon Seng, Osteopore Chief Executive Officer said, "I am delighted to have this opportunity to work with Singular Health to provide them 40 CT scans to train the AI algorithm to recognise skull defects and construct design to fill the defect. The result is remarkable, with a user-friendly interface to assist surgeons in constructing a design to fill the defect. We look forward to a potential commercial outcome between the two companies."

Lim Jing, Osteopore Chief Technology Officer said, "The future of data processing for accurate implant design is here, and Osteopore is excited to be at the leading edge of this development. We look forward to the outcomes of the comparative study and to an impactful outcome for our process and customers."

Thomas Hanly, Singular Health Chief Executive Officer said, "Working with Osteopore on this project provided our team with the ability to focus our research on a commercial outcome. Singular has worked closely with both the CSIRO and Osteopore and this collaborative outcome demonstrates the ability of AI to accelerate the manual processes in the Scan to Surgery workflow. I now look forward to working closely with Osteopore in commercialising our software through their global client network."

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:
Mark Leong
Executive Chairman
Osteopore Limited
+65 9011 7009
Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

About Singular Health Group Ltd

Founded in 2017, Singular Health is a medical technology company that has developed and commercialised the proprietary Volumetric Rendering Platform ("VRP") for the 3D & VR visualisation of anatomy using standard radiological imagery.
Singular Health is committed to developing technologies that provides patients and practitioners alike with access to personalised, enhanced medical data to inform better health decisions and is currently developing and deploying software products that are built upon the proprietary VRP on a global scale through a direct-to-consumer Software-as-a-Service ("SaaS") model.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.